NICE rec­om­mends Bris­tol My­er­s' heart drug Camzyos in UK

Bris­tol My­ers Squibb’s heart drug Camzyos has been rec­om­mend­ed by the Na­tion­al In­sti­tute for Health and Care Ex­cel­lence as the med­ica­tion inch­es clos­er to ap­proval in the UK and Eu­rope.

In fi­nal draft guid­ance re­leased Fri­day, NICE rec­om­mend­ed mava­camten (brand­ed as Camzyos) as an add-on to stan­dard care for symp­to­matic ob­struc­tive hy­per­trophic car­diomy­opa­thy.

Ob­struc­tive HCM is a heart con­di­tion that oc­curs when part of the mus­cu­lar wall in the heart be­comes thick­er, which can then re­duce blood sup­ply to the rest of the body.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.